Navigation Links
Immunosyn Corporation Names Stephen Ferrone as CEO
Date:10/23/2007

LA JOLLA, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) has announced the appointment of Stephen D. Ferrone as the company's Chief Executive Officer, President and board member.

"I am honored to step into this leadership role at Immunosyn and help shape the company's success. I believe we have the potential to improve the quality of life for millions of people who suffer from painful and debilitating diseases," says Ferrone.

Ferrone is a veteran marketing and sales executive with demonstrated national leadership of strategic and tactical initiatives. His extensive career includes nine years of service with ABN AMRO Asset Management and its Investment Funds Services Group as genesis architect of its marketing strategy.

Ferrone is a graduate of Northwestern University and Loyola School of Law and began his professional career in Chicago, Illinois as a felony trial prosecutor for Cook County. He then transitioned to the wealth management industry and became the Regional Marketing Director at Schwab Institutional and the National Sales Director for ABN AMRO, where he set the strategic marketing plan and raised new investment sales of over $9 billion dollars over his nine-year tenure. Recently, Ferrone provided strategic consulting services to the financial and biotech industries where he became associated with the principals of Argyll Biotechnologies.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (OTC Bulletin Board: IMYN) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including auto-immune disorders such as Multiple Sclerosis (MS), neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS) and complications from Diabetic Mellitus such Diabetic Neuropathy (DN) and Diabetic Ulcers (DU).

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Immunosyn Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
2. Vietnamese Scientists Unravel Genetic Code Of Bird Flu Virus
3. Financial Allowances Being Offered To Poor Vietnamese HIV Carriers
4. Gene Bias: Onomastics of Shared Surnames among Men Reveals Genetic links
5. AIDS Funding Grants Dependant on Tracking Patients Names Efficiently
6. Health Minister Wants Names of Uncooperative Hospital Consultants
7. Chinese PLA Names Bogus Army Medical Bodies Selling Fake Drugs
8. Over 50 Vietnamese Girls Faint Due to Mass Hysteria
9. All U.S. States To Begin Names-Based Reporting of HIV Cases by End of 2007
10. Rajasthan Directs Doctors to Prescribe Medicines by Generic Names
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new ... invalid because it does not obey the rules Congress has directed the CBO to ... which the GOP reform would restore. Yet, it estimates a reduction in employer-based coverage ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents ... June 9--24, 2017. This sacred and spiritual journey during the Summer Solstice ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She will ... The majority of cases litigated under ERISA involve claims for long-term disability benefits. ...
(Date:3/24/2017)... ... 24, 2017 , ... Empower Brokerage, located in Southlake, Texas, ... programs. , In February, 2017, Empower Brokerage introduced their new “Performance Partners” program ... to teach how to maximize their sales efforts, as well as how to ...
(Date:3/24/2017)... ... ... “Vintage and Harvest A Cultivation of Christian Love” is the creation of published ... with his wife, Anna Marie. He and his wife are the proud parents of ... author of “Shadow and Substance.” , “Love, the agape kind, is seen as more ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... March 24, 2017 ShangPharma, a ... and cost-effective drug development and discovery services, ... biotechnology industry, announced today the intent for ... will be consolidating the Contract Research Organizations ... Shanghai ChemPartner. These entities include ChemPartner Shanghai, ...
(Date:3/24/2017)... India , March 24, 2017 A ... market has been growing rapidly as the global sales of Adcetris ... the growth in the antibody drug conjugates market is driven by ... of cancer and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly and ... plans to invest $850 million in its U.S. ... across its U.S. enterprise, including research laboratories, manufacturing ... are being driven by demand for Lilly products, ... medicines in development targeting cancer, pain, diabetes and ...
Breaking Medicine Technology: